Thumbs Up/Down: Brent Saunders has the right idea on drug pricing, let's support that
Endpoints assesses the big biopharma R&D stories of the week, with a little added commentary on what they mean for the industry.
Brent Saunders signs off on a pricing manifesto the biopharma industry needs to adopt now.
Once someone prominent stands up and publicly adopts a responsible pricing policy on drugs, promising to hold the lid on annual price hikes, people pay attention. Credit Allergan CEO Brent Saunders with that stand. It’s not everything that needs to be done, but it is a big, big step toward finally lancing the boil of public anger that has been directed against Mylan and pharma in general for routinely pursuing simple price gouging schemes. This isn’t pure altruism. Biopharma needs to protect aggressive pricing models for novel drugs that make a difference. And unless the industry agrees on this one, and follows the Saunders path forward, that crucial strategy is directly threatened. Let’s poll the majors and see how fast we can get a consensus.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.